Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin
2016 ESMO CongressJudith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)
Related Videos
Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near End of Life (French Language Version)
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for meta...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell...
Sumanta K. Pal, MD, on Urothelial Cancer: Results From the CheckMate 275 Trial
Sumanta K. Pal, MD, of the City of Hope, discusses phase II findings on the efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have receive...
Martin H. Schuler, MD, on Gastric and Gastroesophageal Junction Adenocarcinoma: Results of the FAST Study
Martin H. Schuler, MD, of the University Hospital Essen, discusses findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB...
Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate (Italian Language Version)
Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses in Italian high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk...
